Lobna Ouldamer1, Sofiane Bendifallah2, Marie Chas3, Laura Boivin3, Lea Bedouet3, Gilles Body4, Marcos Ballester5, Emile Daraï5. 1. Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069, Université François-Rabelais, Tours, France. Electronic address: l.ouldamer@chu-tours.fr. 2. Department of Obstetrics and Gynaecology, Hôpital Tenon, Paris, France; UMR S 707, Epidemiology, Information Systems, Modeling, Université Pierre et Marie Curie, Paris, France. 3. Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France. 4. Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France; INSERM U1069, Université François-Rabelais, Tours, France. 5. Department of Obstetrics and Gynaecology, Hôpital Tenon, Paris, France; INSERM UMR S 938, Université Pierre et Marie Curie, Paris, France.
Abstract
BACKGROUND: The recently developed MDACC nomogram purports to predict the risk of bone-only metastasis in women with early breast carcinoma based on five clinical and pathological characteristics. We set out to externally validate and assess its robustness using a tertiary breast cancer centre database. METHODS: All consecutive women treated for early breast cancer in our centre between January 1989 and December 2013 and who had all the nomogram variables documented were eligible for analysis. RESULTS: We identified 1255 eligible women for external validation analysis. The median follow-up was 54 months (range: 1-312) and time to initial metastasis 20 months (range: 1-80). The correspondence between the actual bone-only metastasis and the nomogram predictions implied poor calibration of the nomogram in the validation cohort, be it in the whole cohort or when stratified by breast cancer subtype. CONCLUSION: This external validation study of the MDACC nomogram showed limitations in its generalizability to a new and independent European patient population. Copyright Â
BACKGROUND: The recently developed MDACC nomogram purports to predict the risk of bone-only metastasis in women with early breast carcinoma based on five clinical and pathological characteristics. We set out to externally validate and assess its robustness using a tertiary breast cancer centre database. METHODS: All consecutive women treated for early breast cancer in our centre between January 1989 and December 2013 and who had all the nomogram variables documented were eligible for analysis. RESULTS: We identified 1255 eligible women for external validation analysis. The median follow-up was 54 months (range: 1-312) and time to initial metastasis 20 months (range: 1-80). The correspondence between the actual bone-only metastasis and the nomogram predictions implied poor calibration of the nomogram in the validation cohort, be it in the whole cohort or when stratified by breast cancer subtype. CONCLUSION: This external validation study of the MDACC nomogram showed limitations in its generalizability to a new and independent European patient population. Copyright Â